Abstract
Drusen, the yellow deposits under the retina, are composed of lipids and proteins, and represent a hallmark of age-related macular degeneration (AMD). Lipid droplets are also reported in the retinal pigment epithelium (RPE) from AMD donor eyes. However, the mechanisms underlying these disease phenotypes remain elusive. Previously, we showed that Pgc-1α repression, combined with a high-fat diet (HFD), induce drastic AMD-like phenotypes in mice. We also reported increased PGC-1α acetylation and subsequent deactivation in the RPE derived from AMD donor eyes. Here, through a series of in vivo and in vitro experiments, we sought to investigate the molecular mechanisms by which PGC-1α repression could influence RPE and retinal function. We show that PGC-1α plays an important role in RPE and retinal lipid metabolism and function. In mice, repression of Pgc-1α alone induced RPE and retinal degeneration and drusen-like deposits. In vitro inhibition of PGC1A by CRISPR-Cas9 gene editing in human RPE (ARPE19- PGC1A KO) affected the expression of genes responsible for lipid metabolism, fatty acid β-oxidation (FAO), fatty acid transport, low-density lipoprotein (LDL) uptake, cholesterol esterification, cholesterol biosynthesis, and cholesterol efflux. Moreover, inhibition of PGC1A in RPE cells caused lipid droplet accumulation and lipid peroxidation. ARPE19-PGC1A KO cells also showed reduced mitochondrial biosynthesis, impaired mitochondrial dynamics and activity, reduced antioxidant enzymes, decreased mitochondrial membrane potential, loss of cardiolipin, and increased susceptibility to oxidative stress. Our data demonstrate the crucial role of PGC-1α in regulating lipid metabolism. They provide new insights into the mechanisms involved in lipid and drusen accumulation in the RPE and retina during aging and AMD, which may pave the way for developing novel therapeutic strategies targeting PGC-1α.
Similar content being viewed by others
Introduction
Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly. Currently, more than 11 million Americans and over 200 million people worldwide are affected by AMD, and its prevalence is expected to double by 2050 [1]. AMD is a multifactorial disease in which aging is the major factor; however, a complex interplay between genetic, environmental, and metabolic factors contributes to the disease etiology [2].
Drusen, a hallmark of dry AMD, consist of extracellular deposits, which accumulate between the RPE and Bruch’s membrane (BM) [3]. Lipid droplet and lipofuscin accumulations have also been reported in the aging RPE and RPE derived from AMD donor eyes [4].
Several studies have reported on mitochondrial dysfunction, reduced mitochondrial activity, and a switch from oxidative phosphorylation to anaerobic glycolysis, resembling Warburg syndrome in AMD [5,6,7].
Mitochondrial biogenesis is regulated by peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α), which regulates mitochondrial mass through induction of transcriptional machinery [8] and is involved in carbohydrate and lipid metabolism [9].
PGC-1α is reported to influence fatty acid oxidation (FAO) by upregulating the expression of tricarboxylic acid cycle genes of the mitochondrial fatty acid oxidation pathway [10].
In addition, stimulation of PGC-1α has been shown to upregulate the plasma membrane and mitochondrial fatty acid transporters (FAT/CD36, FABPpm, and FATPs) content in skeletal muscle [11].
Lipids can be contained in cells as lipid droplets, which are storage organelles containing neutral lipids and originate from the endoplasmic reticulum (ER). The size, composition, and number of lipid droplets differ between cells and could reflect cellular metabolic states [12]. Accumulation of lipid droplets has also been related to mitochondrial dysfunction as a generalized response to oxidative stress [13].
PGC-1α is also shown to regulate mitochondrial membrane structure and function by metabolic and membrane structural programs in the heart [14].
An important component of mitochondrial membranes is Cardiolipin (CL), which is exclusively synthesized in mitochondria [15]. CL plays an essential role in mitochondrial functions, including mitochondrial coupling and energy production, and its synthesis has been shown to be regulated by PGC-1α in the heart [14, 16].
Studies have reported on the role of PGC-1α in RPE oxidative metabolism and antioxidant defense [17], retinal light sensitivity [18], regulation of normal and pathological retinal angiogenesis [19], and induction of mesenchymal transition in RPE and retinal degeneration [20].
Previously, we showed that heterozygous PGC-1α repression (Pgc-1α+/−) combined with a high-fat diet (HFD) induces AMD-like phenotypes in mice [21]. While a HFD exacerbates lipid accumulation and accelerates induction of disease phenotypes in the RPE and retina of the Pgc-1α+/− mice, as shown by our previous study, we demonstrate here that inhibition of Pgc-1α alone, under a regular diet, can induce RPE and retinal dysfunction and drusen-like deposits in mice.
We also reported dysregulated AMPK-SIRT1-PGC-1α and metabolic pathways [22] and lipid accumulation in the RPE of AMD donor eyes [6]. A recent study also showed that lipid droplet accumulation can induce RPE dysfunction [23].
However, the mechanisms underlying these cellular dysfunctions remain to be elucidated.
Here, we demonstrate the critical roles of PGC-1α in regulating lipid metabolism in RPE. We also show that inhibition of PGC1A in human RPE reduces the expression of genes related to lipid metabolism, inhibits β-oxidation, represses triglyceride synthesis while promoting cholesteryl ester generation, induces lipid droplet accumulation, reduces mitochondrial mass and function, decreases antioxidant enzymes, and thus, increases the susceptibility of the RPE to oxidative stress-induced cell death by peroxidation.
Our data shed light on the mechanisms of lipid accumulation and metabolic dysfunction in RPE and retina and open new avenues for developing novel treatment strategies in AMD.
Materials and methods
Cells
Human RPE (ARPE-19) cells were obtained and validated as previously described [24]. ARPE19 cells were cultured daily in DMEM/F12 medium (11320033; Life Technologies, Carlsbad, CA, USA) supplemented with 10% FBS (10438-026, Life Technologies) and 2 mM GlutaMAX (35650061, Life Technologies).
ARPE19-PGC1A KO cells were generated by CRISPR/Cas9-mediated technology. Specific guide RNAs (gRNAs) were designed using the following link: https://zlab.bio/guide-design-resources and ligated into LentiCRISPR v2 (TLCV2) according to Addgene’s protocol. TLCV2 was a gift from Adam Karpf (Addgene plasmid # 87360; http://n2t.net/addgene:87360 ; RRID:Addgene_87360). The gRNAs used in this study are as follows: PGC1A sgRNA1 (5′–3′): GATACAGACAGCTTTCTGGG, PGC1A sgRNA2 (5′–3′): GCTTTCTGGGTGGACTCAAG. Cells transfected with Control (Scramble) or sgRNAs were selected in complete medium with 2 μg/ml puromycin for 2 weeks, followed by adding 2 μM doxycycline (Dox) for 24 h to induce Cas9-eGFP expression. The ratio of Cas9 positive cells was analyzed by flow cytometry at 48 h post Dox induction. ARPE19-PGC1A KO and Scramble control cells were cultured in complete medium with 2 μg/ml puromycin and 2 μM Dox for 2 weeks to effectively repress PGC1A. Dox was then removed and cells were cultured for an additional week to conduct qPCR and mtDNA copy number assay. Cells deprived of Dox were cultured for two additional weeks to perform Western Blotting, L-Carnitine assay, Fatty acid oxidation assay, lipid peroxidation assay, TMRE-mitochondrial membrane potential assay, mitochondrial staining, and cell viability assay.
Two different siPGC1As: siRNA1 (5′–3′): CAUUUGAGAACAAGACUAU, siRNA2(5′–3′): GAAUUCAUGGAGCAAUAAA, and siControl (5′–3′): AACGUACGCGGAAUACUUCGA were synthesized by Sigma Aldrich and packed by Lipofectamine RNAiMAX Transfection Reagent (13778075, Thermo Fisher Scientific, Waltham, MA, USA), and delivered to ARPE19 cells in Opti-MEM reduced serum media (31985070, Life Technologies). Cells were cultured 4–6 h followed by incubation in complete media. Cells were collected in 72 h for qPCR and western blots.
Animals
All studies involving animals were approved by the Institutional Animal Care and Use Committee of Georgetown University and were in compliance with the Statement for the Use of Animals in Ophthalmic and Vision Research from the Association for Research in Vision and Ophthalmology (ARVO). Heterozygous B6.129S4 (FVB)-Ppargc1atm1Brsp/J mice on a C57BL/6J background purchased from the Jackson Laboratory (Bar Harbor, ME, USA) were bred to generate Pgc-1α+/− and Pgc-1α−/− mice. Animals were kept in a temperature-controlled room on a 12-h dark:12-h light cycle with free access to water and food. Automated genotyping from tail samples was performed by Transnetyx (Cordova, TN, USA). The sample size was chosen based on between-subject variability for each experimental group for in vivo experiments. Mice from both sexes were included in the study. Mice were excluded from the study in case of any apparent pathology, adverse reactions to anesthesia, or abnormal behavior. Mice were randomly incorporated into experimental groups based on genotype. Experiments were performed in a blind and randomized manner.
qRT-PCR
RNA was extracted from harvested cells using the E.Z.N.A Total RNA Kit I (6834-01; Omega Bio-Tek, Norcross, GA, USA). cDNA was synthesized using the Verso cDNA synthesis Kit (AB1453B; Thermo Fisher Scientific) and qPCR amplification was performed with the Maxima SYBR Green/ROX qPCR Master Mix (2X) (K0222, Thermo Fisher Scientific) by loading 10 ng cDNA for each reaction. qPCR primers (Table S1) were designed using PrimerBank (https://pga.mgh.harvard.edu/primerbank/) and synthesized by Integrated DNA Technologies (Coralville, IA, USA).
Western Blotting
For whole-cell protein extraction, collected cells were lysed by T-PER tissue protein extraction reagent (78510, Thermo Fisher Scientific) using protease and phosphatase inhibitor (A32959, Thermo Fisher Scientific). For mitochondrial proteins, mitochondria were isolated with the mitochondria Isolation Kit (89874, Thermo Fisher Scientific). A BCA assay kit was used to determine protein concentration (23227, Thermo Fisher Scientific). 30μg protein samples for each lane were loaded into Tris-glycine gels (8%, 10%, or 12%), and proteins were transferred onto PVDF membranes (IPVH00005; MilliporeSigma, Burlington, MA, USA). Blots were incubated with the primary antibody overnight at 4 °C. The blots were then washed three times and incubated with the secondary antibody for 1 h at room temperature. Corresponding primary antibodies and secondary antibodies with their respective dilutions are listed in Table S2.
l-carnitine assay
l-Carnitine levels were determined by l-Carnitine Quantification Assay Kit (ab83392; Abcam, Waltham, MA, USA). 1.4 × 106 cells for each group were harvested and samples were set up in duplicates. The assay and analysis were performed according to the manufacturer’s protocol. l-Carnitine for each group was calculated using the methods provided by the manufacturer.
Fatty acid oxidation (FAO) assay
FAO activity was measured on cell lysates using the fatty acid oxidation (FAO) assay kit (E-141; Biomedical Research Service, Buffalo, NY, USA). 1 × 106 cells/group were harvested and lysed in 95 μl of 1× lysis solution. BCA protein assay was used to determine lysate protein concentration. The concentration of all samples was equalized to 1 μg/μl using lysis buffer. 20 μl lysate of each sample was added to a 96-well plate in duplicate. Samples were incubated in a 37 °C humidified incubator for 1 h. FAO activity was calculated using manufacturer guidelines.
Lipid peroxidation (MDA) assay
Lipid peroxidation levels of ARPE19-PGC1A KO and Scramble control cells were measured by the Lipid Peroxidation (MDA) Assay Kit (ab118970, Abcam). The relative fluorescence units (RFU) were measured on a 96-well black-bottom flat plate (655086; Greiner Bio-One, Kremsmünster. AT) in duplicates for each sample at Ex/Em=532/553 nm (top read). The concentration of MDA for each group was calculated according to the manufacturer’s instructions.
Lipids droplets staining
ARPE19-PGC1A KO and Scramble control cells were cultured in complete medium with 2 μg/ml puromycin and 2 μM doxycycline for 2 weeks. Cells were then cultured for 6 or 10 additional weeks in DMEM/F12 medium with 15% FBS and 2 μg/ml puromycin. Cells were seeded in 35 mm glass bottom confocal dish (81218-200; Ibidi, Gräfelfing, GER). **All the following steps need to be protected from light**. When cells reached 100% confluency, Lipid Spot 488 was diluted (70065; 1:1000; Biotium, Fremont, CA, USA) in complete medium and cells were incubated with the dye at 37 °C for 1 h. Cells were gently washed with PBS one time and fixed in 4% formaldehyde for 15 min at room temperature, and permeabilized with 0.1% Triton™ X-100 for 10 min. Cells were blocked with 5% BSA for 1 h at room temperature, flowed by 3 washes by PBS. Cells were incubated with ZO-1 Alexa Fluor® 594 conjugated antibody (339194, Thermo Fisher Scientific) at 5 µg/ml (1:100) in 1% BSA for 3 h at room temperature. Cell nuclei were stained with DAPI (0100-20; Southern Biotech, Birmingham, AL, USA). Images were acquired with an ECHO Revolve Microscope (ECHO, San Diego, CA, USA). Green fluorescence of lipid droplets in three random areas from each image were quantified by ImageJ to relatively quantify lipid droplets for each group.
mtDNA copy number
Genomic DNA of RPE cells were extracted by the DNeasy Blood &Tissue Kit (69504; Qiagen, Venlo, NL). The mitochondrial DNA (mtDNA) gene ND1 and the nuclear DNA (nDNA) gene ACTB were amplified by CFX Connect Real-Time PCR detection system (Bio-Rad, Hercules, CA, USA). The qPCR protocol was performed as previously described [24]. Cycle threshold values for each sample were analyzed to determine the relative DNA copy number by a ratio of mitochondrial DNA to genomic DNA.
Mitochondrial staining
Cells were seeded in 35 mm glass bottom confocal dish (81218-200, Ibidi) for 24 h, 5000 cells/dish. Freshly prepared complete medium containing 100 nM MitoViewTM Green (70054, Biotium) and 10ug/ml Hoechst33342 (for nuclei staining; H3570, Thermo Fisher Scientific) was directly added to the cells. Cells were incubated for 30 min at 37 °C and protected from light. Images from living cells were captured by the ECHO Revolve Microscope.
TMRE-mitochondrial membrane potential assay
ARPE19-PGC1A KO and Scramble control cells were seeded on a 96-well plate (3603; Corning, NY, USA), 0.85 × 105 cells/well in triplicate were cultured for 12 h, and the TMRE- Mitochondrial Membrane Potential Assay was performed according to the manufacturer’s instructions (ab113852, Abcam, MA, USA). TMRE values were measured at Ex/Em = 549/575 nm (bottom read).
Cell viability assay
Cells were seeded on a 96-well plate in triplicate for 48 h, at the density of 1.4 × 104 cells/well (3603, Corning), followed by incubation with a range of H2O2 concentrations (0–1 mM) for 24 h. Cell viability was measured with PrestoBlue Cell viability Reagent (A13261; Invitrogen, Waltham, MA, USA). Fluorescence was read through the top at Ex/Em = 560 nm/590 nm.
Cardiolipin assay
2 × 107 cells from ARPE19-PGC1A KO group and Scramble group were collected to isolate the mitochondria using the Mitochondria Isolation Kit (89874, ThermoFisher Scientific). The concentration of mitochondrial lysate was determined by BCA assay kit (23227, ThermoFisher Scientific). 40μg mitochondrial protein for each group was loaded for the measurement of Cardiolipin content by Cardiolipin Assay kit (ab241036, Abcam, MA, USA). Cardiolipin concentrations were reported as nmol of Cardiolipin/ mg mitochondrial protein.
Electroretinography
Mice were 8 months old at the time of analysis. Following overnight dark-adaptation, mice were anesthetized with 3.0% isoflurane. Under dim red light, they were transferred on a heating pad at 37 °C where 1.5% isoflurane was continuously delivered through a nose cone for maintenance. 2.5% Phenylephrine: 1% Tropicamide eye drops at a 2:1 ratio was used to induce mydriasis. Celeris stimulator-electrodes (Diagnosys LLC, Lowell, MA, USA) were positioned on each cornea. GenTeal (0.3% hypromellose; Alcon, Fort Worth, TX, USA) was used to both facilitate contact of the cornea with the electrodes and lubricate the eyes. ERG responses were recorded using the Diagnosys Celeris system and the Espion V6 software.
Scotopic flash ERGs were recorded using a white flash (6500 K) at seven ascending stimulus intensities ranging from 0.001–10.0 cd s/m2. Responses were an average of three sweeps. The a-wave was measured from the pre-stimulus baseline to the trough of the initial negative wave. The b-wave amplitude was measured at the highest positive peak following the trough of the a-wave. The c-wave was recorded at a stimulus intensity of 150.0 cd s/m2; c-wave amplitude was measured from the pre-stimulus baseline to the highest recorded peak. Implicit times were recorded as the duration after the flash onset and the time to peak.
Fundus photography
Animals were prepared as described above. Fundus images were acquired on live animals using the OcuScience iVivo Funduscope (OcuScience, Henderson, NV, USA). Adobe Photoshop was used to process the images. Fundus images were analyzed by counting drusen-like deposits that appear as bright spots on the fundus. The analysis was carried out by three independent investigators. Number of deposits observed from both eyes were averaged for each animal.
Statistical analysis
For statistical analysis of dark-adapted flash ERG series, two-way repeated measures ANOVA (factors: genotype and luminance) and post hoc Sidak correction for multiple comparisons was used. For the comparison of c-wave data across three genotypes, one-way ANOVA with post hoc Sidak correction was used. Responses from both eyes were averaged for each data point. Data met assumptions of normality as tested by the Shapiro-Wilk test and homogeneity of variance. For comparison of fundus photographs across three groups, data were log transformed and analyzed by one-way ANOVA with post hoc Sidak correction. Data are presented as mean ± SEM; GraphPad Prism 9.5.0 was used for analysis.
For in vitro experiments, two-tailed unpaired t-test was performed for comparison between two groups. Data are presented as mean ± SD or mean ± SEM from three independent experiments. Significance was considered when *P ≤ 0.05 and was indicated in the text as follows: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001.
Results
PGC-1α knockout and heterozygous mice exhibit impaired photoreceptor and RPE function and drusen-like deposits
In order to evaluate the overall ocular health of the Pgc-1α+/− and Pgc-1α−/−, we performed fundus photography. Fundus images revealed drusen-like deposits in Pgc-1α+/− and Pgc-1α−/− as compared to WT mice. These deposits appeared to be bigger in size in the Pgc-1α−/− compared to the Pgc-1α+/− (Fig. 1A). Additionally, we observed a significantly higher number of drusen-like deposits in Pgc-1α+/− and Pgc-1α−/− mice compared to WT controls, as well as an increased amount in Pgc-1α−/− vs. Pgc-1α+/− (adj. P < 0.0001 for all three comparisons) (Fig. 1B).
Analysis of c-wave ERG revealed significantly reduced RPE function both in the Pgc-1α+/− (adjusted ANOVA P = 0.0066) and Pgc-1α−/− (adj P = 0.0002), compared to WT mice (Fig. 1C, D). Although we observed a trend towards reduced c-waves between Pgc-1α−/− and Pgc-1α+/−, the difference was not statistically significant (Fig. 1D). c-wave implicit times were significantly delayed in Pgc-1α+/− mice compared with WT controls (adj. P = 0.0409), and a trend was observed towards delayed c-wave responses in Pgc-1α−/− mice as compared to WT controls; however, the difference was not statistically significant, probably due to a smaller sample size in Pgc-1α−/− mice (Fig. 1E).
Scotopic flash ERG measurements of a-waves (reflecting rod photoreceptor functions) at seven stimulus intensities ranging from 0.001–10.0 cd s/m2 revealed significantly reduced a-waves in Pgc-1α−/− mice as compared to WT at stimulus intensities ranging from 0.1-10.0 cd·s/m2 (adj. P = 0.0003, 0.0008, 0.0005, <0.0001, <0.0001, respectively) (Fig. 2A–C). Pgc-1α+/− mice, compared to WT, had significantly reduced a-wave amplitudes at the maximum stimulus intensity of 10.0 cd s/m2 (adj. P = 0.0281). Moreover, significant differences in a-wave amplitude were observed between Pgc-1α−/− and Pgc-1α+/− mice at all intensities in the range of 0.1–10.0 cd·s/m2 (adj. P = 0.0184, 0.0152, 0.0186, 0.0054, 0.03, respectively) (Fig. 2B). Analyses of a-wave implicit times revealed no significant differences (Fig. 2F).
Analyses of b-waves (a response primarily contributed by the bipolar-ON cells) revealed reduced b-wave amplitudes in Pgc-1α−/− as compared to WT mice at all intensities in the range of 0.01-10.0 cd·s/m2 (adj. P = 0.0019, <0.0001, <0.0001, <0.0001, <0.0001, <0.0001, respectively). Pgc-1α+/− mice, at the stimulus intensities of 5.0–10.0 cd·s/m2 had significantly reduced b-wave amplitudes compared to WT controls (adj. P = 0.0336, 0.0136, respectively) (Fig. 2A, D, E). In addition, the b-wave amplitudes of Pgc-1α−/− were reduced compared to Pgc-1α+/− mice at all intensities ranging from 0.1–10.0 cd s/m2 (adj. P = 0.0189, 0.0101, 0.0153, 0.0125, 0.0451, respectively) (Fig. 2D). No differences in b-wave implicit times were observed across the three groups (Fig. 2F).
Inhibition of PGC1A reduced the expression of PPARs and LXRs, declined fatty acid β-oxidation, and increased lipid peroxidation in human RPE cells
PGC-1α functions as a regulator of lipid metabolic pathways [10] by influencing various transcription factors and nuclear hormone receptors, including PPARα, PPARβ, PPARγ, NR1H3 & NR1H2 (encode LXRα & LXRβ, respectively). These transcription factors were reported to be involved in different stages of lipid metabolism such as fatty acid (FA) uptake [25], FA cytoplasmic transport [11], lipid lysosomal degradation [26], fatty acid β-oxidation (FAO) [27], and lipid biosynthesis [27]. We generated the ARPE19-PGC1A KO cell line mediated by CRISPR-Cas9 technology to inhibit PGC1A gene expression (S-Fig. 1) and to subsequently explore the mechanisms by which PGC1α regulates lipid metabolism in RPE cells. qPCR and Western blot analyses showed a significant reduction in mRNA and protein levels of PPARα, PPARβ, PPARγ, NR1H3 & NR1H2 in ARPE19-PGC1A KO as compared to Scramble-gRNA (control) cells (Fig. 3A–C). To confirm that the data obtained by CRISPR-Cas9 inhibition of PGC1A in RPE are not due to off-target effects of CRISPR-Cas9, we used siRNA to inhibit PGC1A in ARPE19 cells. Similar results were observed when PGC1A was inhibited by siRNA in ARPE19 cells (S-Fig. 2A–C).
Long-chain fatty acids are converted into their active form, the acyl-CoAs, by acyl-CoA synthetase long-chain family member (ACSL) for both lipid synthesis and lipid degradation via FAO [28]. Fatty acids are transported into mitochondrial matrix by the sequential action of carnitine palmitoyltransferase I (CPT1) in the outer mitochondrial membrane and carnitine palmitoyltransferase II (CPT2) in the inner membrane, along with carnitine-acylcarnitine translocase [29]. Mitochondrial β-oxidation of long-chain fatty acids is initiated by the medium-chain specific Acyl-Coenzyme A dehydrogenase (ACADM) [29].
Our data showed a significant decrease in CPT1A, CPT2, ACSL1, and ACADM gene expression (Fig. 3A). Western blot analyses further revealed reduced protein levels of CPT1A, CPT2, ACSL1, and ACADM in ARPE19-PGC1A KO as compared to control cells (Fig. 3D, E). We observed similar results when we used siRNA to knock down PGC1A in ARPE19 cells (S-Fig. 2A–C). In addition, L-Carnitine activity was decreased in ARPE19-PGC1A KO cells (Fig. 3F). As CPT1A transports FAs into the mitochondria in a carnitine-dependent manner, blunted L-Carnitine activity further exacerbates FAO deficiency. The FAO assay showed a significant reduction in FAO efficiency in ARPE19-PGC1A KO as compared to control cells (Fig. 3G). Analysis of malondialdehyde (MDA) concentration revealed increased lipid peroxidation in ARPE19-PGC1A KO as compared to control cells (Fig. 3H).
Inhibition of PGC1A induces lipid droplet generation in RPE cells
We cultured ARPE19-PGC1A KO cells and inhibited PGC1A expression by doxycycline treatment for 14 days. Then ARPE19-PGC1A KO and control cells were cultured in complete medium with 15% FBS, which supplies higher lipids, triglycerides, and cholesterol to cells and mimics a mild high-fat culturing condition. Immunostaining analyses revealed that 6 weeks post 15% FBS medium treatment multiple, small lipid droplets (green) appeared in the cytoplasm of ARPE19-PGC1A KO cells. Under normal culture conditions, ARPE19 cells can uptake fatty acids and process them by β-oxidation for cell energy needs. Therefore, we did not observe lipid droplet accumulation in the control group at 6 weeks post 15%FBS medium treatment (Fig. 4A, C). After 10 weeks incubation with medium containing 15% FBS, lipid droplets were enlarged, and the tight junctions (ZO-1, red) were dramatically disarranged and hexagonal RPE morphology was disrupted, showing an epithelial-to-mesenchymal transition in PGC1A KO cells. We also observed minor lipid droplet formation in ARPE19 Scramble cells, since long-term culture of RPE cells in the presence of 15% FBS gradually induces lipid droplets (Fig. 4B, C).
Inhibition of PGC1A promotes cholesterol esterification while reducing triglyceride biosynthesis, limits uptake of exogenous LDL, decreases cholesterol efflux, and lowers the inhibition of the rate-limiting enzyme in cholesterol biosynthesis, HMGCR, in RPE cells
Lipid droplets (LDs) are organelles that store neutral lipids which are mainly composed of triglycerides (TAG) and cholesteryl esters (CE) [30]. Cells can catalyze the conversion of diacylglycerol and fatty acyl CoA to TGA by diacylglycerol O-acyltransferase 1 and 2 (DGAT1 and DGAT2) [31] and/or catalyze the formation of CE from fatty acids (FAs) and cholesterol, or retinol by sterol O-acyltransferase 1 and 2 (SOAT1 and SOAT2) [32].
To investigate the mechanism by which lipid droplets accumulate in ARPE19-PGC1A KO cells, we verified mRNA and protein levels of DGAT1, DGAT2, SOAT1, and SOAT2. Our data showed that both mRNA expression and protein levels of DGAT1 and DGAT2 were significantly decreased in ARPE19-PGC1A KO as compared to control cells (Fig. 5A–C). However, SOAT1 and SOAT2 protein levels were significantly increased (Fig. 5B, C), while no significant changes were observed in their mRNA levels (Fig. 5A). These findings suggest that LDs shown in Fig. 4 may dominantly result from the formation of CE rather than TAG synthesis.
Exogenous FAs and lipids (such as cholesterol and retinol) can be catalyzed into CEs which ultimately contribute to the formation of LDs, particularly in conditions of impaired fatty acid oxidation. To explore whether CEs in LDs are mainly derived from FAs or cholesterol, we first examined the expression of three fatty acid transport-related proteins, namely FATP2, FABP4, and CD36, which are closely associated with intracellular FA accumulation. FATP2, also known as SLC27A2, can mediate the uptake of exogenous FAs or lipids and convert free long-chain fatty acids into fatty acyl-CoA esters, thereby playing a key role in lipid biosynthesis and degradation [33]. Elevation of FATP2 levels in the liver results in increased fat accumulation and inflammation [34]. FATP2 abundance also contributes to excessive FA uptake and impaired FAO activities in renal tubular epithelial cells [35]. However, in our study, we observed that inhibition of PGC1A led to the reduction of FATP2 at both the mRNA and protein levels (Fig. 5A, D, E). Fatty acid-binding protein 4 (FABP4) is a member of the fatty acid-binding protein family and acts as an intracellular lipid chaperone to regulate lipid trafficking in cells. It has been reported that upregulation of FABP4 promotes the deposition of LDs in macrophages [36]. Here, we found that inhibition of PGC1A in ARPE19 cells induced a decrease in FABP4 protein levels, while mRNA levels were significantly increased (Fig. 5A, D, E). CD36 is also known as a pivotal long-chain fatty acid transporter that contributes to fatty acid accumulation [37] and negative regulation of lipophagy [38]. We found no change in the protein levels of CD36 in ARPE19-PGC1A KO compared to control cells, while its mRNA levels were significantly increased (Fig. 5A, D, E). These findings suggest that the CEs in LDs were not dominantly converted from exogenous FAs transported by FATP2, FABP4, and CD36.
Subsequently, we assessed the expression of LDLR, involved in the uptake of exogenous cholesterol. Surprisingly, inhibition of PGC1A also led to a significant reduction in LDLR expression (Fig. 5F, G). Furthermore, we measured the levels of cholesterol efflux-related proteins ABCA1/ ABCG1/ABCG5 and found that their levels were significantly decreased in ARPE19-PGC1A KO compared to control cells (Fig. 5F, G).
To further explore the possibility of endogenous cholesterol biosynthesis, we tested HMG-CoA reductase (HMGCR), the rate-limiting enzyme in cholesterol synthesis [39], and analyzed its phosphorylation at Ser872. In humans, decreased phosphorylation of HMGCR (p-HMGCR) at Ser872 is linked to increased HMGCR activity [40]. Our data showed that inhibition of PGC1A significantly decreased phosphorylation levels of HMGCR (Fig. 5H, I), suggesting that HMGCR activity is increased in ARPE19-PGC1A KO cells. It has been reported that AMP-activated protein kinase (AMPK) is the dominant upstream kinase involved in phosphorylation of HMGCR [41, 42]. AMPK is activated upon its phosphorylation at Thr172 and, in turn, inactivates HMGCR via phosphorylation of the enzyme at Ser872. Thus, we examined AMPKα and its phosphorylation (p-AMPKα) at Thr172, and found that inhibition of PGC1A led to a significant reduction in p-AMPKα levels (Fig. 5J, K). Our data indicates that PGC1A inhibition decreases the kinase activity of AMPK and, consequently, elevates HMGCR activity.
These findings suggest that, while the transport of exogenous LDL was decreased by PGC1A inhibition, cholesterol biosynthesis was induced by increased HMGCR activity in ARPE19-PGC1A KO cells. Additionally, reduced cholesterol efflux might contribute to the formation of cholesterol esters and, ultimately, the generation of lipid droplets.
Inhibition of PGC1A in human RPE cells downregulates mitochondrial biosynthesis and activity, decreases antioxidant enzymes and mitochondrial membrane potential, and increases susceptibility to oxidative stress
PGC-1α regulates the expression of nuclear and mitochondrial genes that encode components of the electron transport system and oxidative phosphorylation (OXPHOS) machinery via the coactivation of nuclear respiratory factors 1 (NRF1) and estrogen-related receptors α, β, and γ (ERR-α, -β and -γ) [9]. These effects can further modulate the expression of mitochondrial transcription factor A (TFAM), which is known to control mitochondrial DNA (mtDNA) replication and transcription, therefore regulating cellular oxidative metabolism [9].
qPCR analyses showed a significant decrease in mRNA levels of ERRα, ERRγ, NRF1 and TFAM in ARPE19-PGC1A KO compared to control cells, whereas ERRβ mRNA levels were significantly increased (Fig. 6A). We inhibited PGC1A with siRNA and obtained similar results in ARPE19 cells (S-Fig. 2A, B). Furthermore, mitochondrial DNA (mtDNA) copy number was reduced in ARPE19-PGC1A KO cells (Fig. 6F). MitoView staining revealed a significant reduction of mitochondrial mass consistent with reduced mtDNA copy number in ARPE19-PGC1A KO (Fig. 6B).
Analyses of mitochondrial dynamics-related genes, DRP1 and OPA1, and mitochondrial respiratory chain complex1 core subunits genes, NDUFS2 and NDUFS8, confirmed a reduction in their mRNA levels in ARPE19-PGC1A KO compared to control cells (Fig. 6A). Measurement of mitochondrial membrane potential revealed a significant decrease in ARPE19-PGC1A KO compared to control cells (Fig. 6E).
Previous studies have confirmed that PGC1α interacts with nuclear factor E2-related factor 2 (NFE2L2), regulating its expression and activity [43, 44]. NFE2L2 can regulate the antioxidant response to protect cells against oxidative damage by inducing the production of antioxidant enzymes, including superoxide dismutase 1/2 (SOD1/2) and catalase (CAT) [45, 46]. In our current research, we found that inhibition of PGC1A downregulated mRNA levels of NFE2L2, SOD1, SOD2, and CAT (Fig. 6A) and reduced protein levels of NFE2L2, SOD2, and Catalase (Fig. 6C, D). We did not observe a reduction in the nuclear localization of NFE2L2 (S-Fig. 3) in ARPE19-PGC1A KO cells, suggesting that the downregulation of SOD1, SOD2, and CAT mRNA levels originated from decreased NFE2L2 protein levels.
Our cell viability analyses of ARPE19-PGC1A KO under increasing concentrations of H2O2 revealed increased susceptibility to oxidative stress compared to control cells at 24 h
of H2O2 incubation (Fig. 6G). Similar results were obtained when we used siRNA to inhibit PGC1A in ARPE19 cells (S-Fig. 2D).
Inhibition of PGC1A induces loss of cardiolipin in human RPE cells
Cardiolipin (CL) is a unique dimeric glycerophospholipid localized almost exclusively to the mitochondria in mammalian cells [47], and plays a critical role in the homeostasis of the mitochondrial membrane, thus influencing mitochondrial OXPHOS and FAO.
To elucidate the mechanism by which PGC1A inhibition affects cardiolipin synthesis, we performed qPCR to measure mRNA levels of genes involved in cardiolipin synthesis pathway, CDS1, PGS1, PTPMT1, CRLS1, and TAFAZZIN, and found their expression to be downregulated in ARPE19-PGC1A KO cells (Fig. 7A). Our Western blot data showed that protein levels of PGS1, PTPMT1, CRLS1, and TAFAZZIN were significantly reduced (Fig. 7B,C). Furthermore, we applied equal amounts of mitochondrial protein from the ARPE19-PGC1A KO and the control groups to test the mitochondrial cardiolipin content, and we found that inhibition of PGC1A significantly decreased cardiolipin levels (Fig. 7D). These data suggest that the loss of cardiolipin in ARPE19-PGC1A KO cells resulted from the inhibition of cardiolipin synthesis rather than reduced mitochondrial mass as shown in Fig. 6B.
Discussion
Our study reports on essential roles for PGC-1α in RPE metabolic homeostasis, lipid droplet formation, mitochondrial functions, and cellular resistance to oxidative stress. Hallmark phenotypic and functional changes associated with PGC-1α downregulation in mice include RPE, retinal dysfunction, and lipid deposits as observed by ERG and funduscopy, respectively. The inhibition of PGC1A in vitro in the RPE induced dysfunction of lipid metabolism and FA β-oxidation, accumulation of lipid droplets, reduction of triglyceride biosynthesis, and induction of cholesteryl ester conversion. PGC1A deficiency reduced the exogenous uptake of LDL and decreased cholesterol efflux while enhancing the activation of HMGCR, the rate-limiting enzyme in cholesterol biosynthesis. PGC1A inhibition also resulted in the downregulation of mitochondrial biosynthesis, dynamics, and activity-related genes, reduction of mitochondrial membrane potential and antioxidant enzymes, and elevation of RPE susceptibility to oxidative stress and cell death via lipid peroxidation. Collectively, our study reveals that inhibition of PGC-1α contributes to the formation of AMD-like phenotypes in the RPE and induces retinal degeneration by dysregulating lipid metabolism.
RPE and retinal degeneration in Pgc-1α knockout and heterozygous mice
A growing body of evidence suggests that PGC-1α might have important implications in RPE and retinal function [17,18,19,20]. However, the mechanisms by which PGC-1α regulates RPE and retinal function remain to be elucidated.
We have previously shown that Pgc-1α repression combined with a high-fat diet can induce drastic AMD-like phenotypes in mice [21]. Since PGC-1α is identified as a key regulator of lipid and metabolic regulation [10], a combination of a high-fat diet and Pgc-1α repression can accelerate and exacerbate the formation of disease phenotypes in mice.
Here, we show that inhibition of Pgc-1α alone can also affect RPE and retinal function.
We analyzed the RPE and retinal health and function in Pgc-1α+/− and Pgc-1α−/− mice using fundus photography and ERG. Our fundus imaging showed bright spots in the RPE of Pgc-1α+/− and Pgc-1α−/− mice resembling drusen deposits in humans. The ERG confirmed retinal degeneration, shown by a significant reduction in a- and b-waves, and RPE dysfunction, shown by a significant decrease in c-waves in Pgc-1α+/− and Pgc-1α−/− mice. A recent study on the RPE-specific PGC-1α inhibition in mice showed a decrease in a-, b- and c-waves [20]. Here, we show RPE and retinal degeneration in Pgc-1α+/− mice, which indicates that partial inhibition of Pgc-1α can also induce RPE and retinal degeneration over time. These observations are physiologically more relevant to human conditions where PGC-1α expression could be declined by aging [48, 49].
Lipid droplet generation and lipid metabolism in RPE
Drusen, formed between the RPE and Bruch’s membrane, are a distinctive feature of dry AMD and contribute to RPE and photoreceptor degeneration [23]. A recent study demonstrated impaired cholesterol efflux in the RPE of individuals with juvenile macular degeneration [50]. However, the mechanisms underlying these cellular dysfunctions remain to be elucidated.
To investigate the role of PGC-1α in lipid metabolism in RPE, we used CRISPR/Cas9 gene editing to inhibit PGC1A expression in ARPE19 cells. ARPE19-PGC1A KO cells showed elevated lipid droplet generation, which increased in size with time in culture. These observations indicate a direct role for PGC-1α in regulating lipid droplet formation in the RPE and suggest that the pharmacological activation of PGC-1α might be beneficial in reducing lipid and drusen formation in AMD patients. These data also support a role for PGC-1α in AMD, as we have previously reported lipid droplet accumulation [6] and dysregulated AMPK-SIRT1-PGC-1α and metabolic pathways [22] in the RPE derived from AMD donor eyes [23].
To delineate the mechanism by which PGC-1α regulates lipid droplet generation in RPE, we measured the expression of genes and proteins responsible for TAG synthesis and cholesterol esterification. Our data showed that increased lipid droplet formation under PGC-1A inhibition was not due to the synthesis of TAG but rather derived from cholesterol esterification catalyzed by SOAT1 and SOAT2.
PGC1A inhibition also impaired the regular uptake of exogenous FAs mediated by FATP2 and FABP4 and limited the exogenous LDL uptake since we observed lower LDLR protein levels in PGC1A KO cells. However, PGC1A deficiency enhanced the activation of HMGCR via a decrease of p-HMGCR at Ser872 achieved by downregulating p-AMPK at Thr172, suggesting elevated cholesterol biosynthesis. Moreover, our data demonstrated decreased ABCA1/ABCG1/ABCG5 protein levels, indicating reduced cholesterol efflux. These results suggest that lipid droplet generation in ARPE19-PGC1A KO cells is likely due to dysfunctional FAO, excessive cholesterol biosynthesis and esterification, and deficient cholesterol efflux.
Mitochondrial biosynthesis and activity, oxidative stress, and mitochondrial membrane homeostasis in RPE
PGC-1α, a crucial regulator of mitochondrial biogenesis, plays a pivotal role in increasing mitochondrial mass and activity [9]. Previously, we showed reduced mitochondrial Complex I activity and mtDNA copy number in Pgc-1α+/− mice [21]. Another study showed that PGC-1α silencing induced mitochondrial dysfunction and oxidative stress in RPE [20].
To further investigate the role of PGC-1α in mitochondrial activity and integrity, we measured the expression of mitochondrial activity- and dynamic-related genes and mtDNA copy number, all of which were declined in ARPE19-PGC1A KO as compared to control cells. Moreover, mitochondrial mass and membrane potential were significantly reduced in ARPE19-PGC1A KO compared to control cells. The antioxidant enzymes SOD2 and Catalase were also repressed in ARPE19-PGC1A KO cells due to reduced expression of NFE2L2, which regulates the transcription of SOD2 and CAT.
Analysis of cell viability revealed increased susceptibility to oxidative stress-induced cell death in ARPE19-PGC1A KO, possibly due to increased lipid peroxidation and oxidative stress.
CL, a diphosphatidylglycerol, is exclusively synthetized and primarily localized in the mitochondria [15, 47]. It plays a significant role in mitochondrial membrane homeostasis and influences OXPHOS and FAO12. Our investigation into the role of PGC-1α in CL regulation has yielded intriguing results. We discovered that CL content decreases upon PGC1A inhibition, significantly reducing the expression of genes and proteins responsible for CL biosynthesis. These findings highlight the essential role of PGC-1α in mitochondrial membrane homeostasis, activity, and dynamics and open up exciting avenues for future research in this field.
Collectively, our data reveal essential functions for PGC-1α in lipid metabolism, lipid droplet formation, mitochondrial activity, maintenance of mitochondrial homeostasis, and lipid peroxidation in the RPE. Our findings suggest that reduction of PGC-1α activity during aging could contribute to RPE senescence, retinal degeneration, and consequently, AMD pathophysiology. Our observations open new avenues for developing targeted treatment strategies for AMD. Figure 8 recapitulates the role of PGC-1α in lipid metabolism in the RPE.
Data availability
All data generated in this study are included in the article and the Supplementary files. Additional data can be shared by the corresponding author upon reasonable request.
References
Rein DB, Wittenborn JS, Zhang X, Honeycutt AA, Lesesne SB, Saaddine J. Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments. Arch Ophthalmol. 2009;127:533–40.
Nowak JZ. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep. 2006;58:353–63.
Abdelsalam A, Del Priore L, Zarbin MA. Drusen in age-related macular degeneration: pathogenesis, natural course, and laser photocoagulation-induced regression. Surv Ophthalmol. 1999;44:1–29.
Wolf G. Lipofuscin and macular degeneration. Nutr Rev. 2003;61:342–6.
Karunadharma PP, Nordgaard CL, Olsen TW, Ferrington DA. Mitochondrial DNA damage as a potential mechanism for age-related macular degeneration. Invest Ophthalmol Vis Sci. 2010;51:5470–9.
Golestaneh N, Chu Y, Xiao YY, Stoleru GL, Theos AC. Dysfunctional autophagy in RPE, a contributing factor in age-related macular degeneration. Cell Death Dis. 2017;8:e2537.
Samra YA, Zaidi Y, Rajpurohit P, Raghavan R, Cai L, Kaddour-Djebbar I, et al. Warburg effect as a novel mechanism for homocysteine-induced features of age-related macular degeneration. Int J Mol Sci. 2023;24:1071.
Chen L, Qin Y, Liu B, Gao M, Li A, Li X, et al. PGC-1alpha-mediated mitochondrial quality control: molecular mechanisms and implications for heart failure. Front Cell Dev Biol. 2022;10:871357.
Liang H, Ward WF. PGC-1alpha: a key regulator of energy metabolism. Adv Physiol Educ. 2006;30:145–51.
Cheng CF, Ku HC, Lin H. PGC-1alpha as a pivotal factor in lipid and metabolic regulation. Int J Mol Sci. 2018;19:3447.
Supruniuk E, Miklosz A, Chabowski A. The implication of PGC-1alpha on fatty acid transport across plasma and mitochondrial membranes in the insulin sensitive tissues. Front Physiol. 2017;8:923.
Olzmann JA, Carvalho P. Dynamics and functions of lipid droplets. Nat Rev Mol Cell Biol. 2019;20:137–55.
Lee SJ, Zhang J, Choi AM, Kim HP. Mitochondrial dysfunction induces formation of lipid droplets as a generalized response to stress. Oxid Med Cell Longev. 2013;2013:327167.
Lai L, Wang M, Martin OJ, Leone TC, Vega RB, Han X, et al. A role for peroxisome proliferator-activated receptor gamma coactivator 1 (PGC-1) in the regulation of cardiac mitochondrial phospholipid biosynthesis. J Biol Chem. 2014;289:2250–9.
Schlame M, Haldar D. Cardiolipin is synthesized on the matrix side of the inner membrane in rat liver mitochondria. J Biol Chem. 1993;268:74–9.
Prola A, Blondelle J, Vandestienne A, Piquereau J, Denis RGP, Guyot S, et al. Cardiolipin content controls mitochondrial coupling and energetic efficiency in muscle. Sci Adv. 2021;7:eabd6322.
Iacovelli J, Rowe GC, Khadka A, Diaz-Aguilar D, Spencer C, Arany Z, et al. PGC-1alpha induces human RPE oxidative metabolism and antioxidant capacity. Investig Ophthalmol Vis Sci. 2016;57:1038–51.
Egger A, Samardzija M, Sothilingam V, Tanimoto N, Lange C, Salatino S, et al. PGC-1 alpha determines light damage susceptibility of the murine retina. PLoS ONE. 2012;7:e31272.
Saint-Geniez M, Jiang A, Abend S, Liu L, Sweigard H, Connor KM, et al. PGC-1alpha regulates normal and pathological angiogenesis in the retina. Am J Pathol. 2013;182:255–65.
Rosales MAB, Shu DY, Iacovelli J, Saint-Geniez M. Correction: Loss of PGC-1alpha in RPE induces mesenchymal transition and promotes retinal degeneration. Life Sci Alliance. 2019;2:e201900436.
Zhang M, Chu Y, Mowery J, Konkel B, Galli S, Theos AC, et al. Pgc-1alpha repression and high-fat diet induce age-related macular degeneration-like phenotypes in mice. Dis Model Mech. 2018;11:dmm032698.
Zhang M, Jiang N, Chu Y, Postnikova O, Varghese R, Horvath A, et al. Dysregulated metabolic pathways in age-related macular degeneration. Sci Rep. 2020;10:2464.
Yako T, Otsu W, Nakamura S, Shimazawa M, Hara H. Lipid droplet accumulation promotes RPE dysfunction. Int J Mol Sci. 2022;23:1790.
Zhou S, Hum J, Taskintuna K, Olaya S, Steinman J, Ma J, et al. The anti-aging hormone klotho promotes retinal pigment epithelium cell viability and metabolism by activating the AMPK/PGC-1alpha pathway. Antioxidants. 2023;12:385.
Volcik KA, Nettleton JA, Ballantyne CM, Boerwinkle E. Peroxisome proliferator-activated receptor [alpha] genetic variation interacts with n-6 and long-chain n-3 fatty acid intake to affect total cholesterol and LDL-cholesterol concentrations in the Atherosclerosis Risk in Communities Study. Am J Clin Nutr. 2008;87:1926–31.
Sinha RA, Rajak S, Singh BK, Yen PM. Hepatic lipid catabolism via PPARalpha-lysosomal crosstalk. Int J Mol Sci. 2020;21:2391.
Bougarne N, Weyers B, Desmet SJ, Deckers J, Ray DW, Staels B, et al. Molecular Actions of PPARalpha in Lipid Metabolism and Inflammation. Endocr Rev. 2018;39:760–802.
Ellis JM, Li LO, Wu PC, Koves TR, Ilkayeva O, Stevens RD, et al. Adipose acyl-CoA synthetase-1 directs fatty acids toward beta-oxidation and is required for cold thermogenesis. Cell Metab. 2010;12:53–64.
Houten SM, Wanders RJ. A general introduction to the biochemistry of mitochondrial fatty acid beta-oxidation. J Inherit Metab Dis. 2010;33:469–77.
Onal G, Kutlu O, Gozuacik D, Dokmeci Emre S. Lipid droplets in health and disease. Lipids Health Dis. 2017;16:128.
Hung YH, Carreiro AL, Buhman KK. Dgat1 and Dgat2 regulate enterocyte triacylglycerol distribution and alter proteins associated with cytoplasmic lipid droplets in response to dietary fat. Biochim Biophys Acta Mol Cell Biol Lipids. 2017;1862:600–14.
Walther TC, Farese RV Jr. Lipid droplets and cellular lipid metabolism. Annu Rev Biochem. 2012;81:687–714.
Black PN, Ahowesso C, Montefusco D, Saini N, DiRusso CC. Fatty acid transport proteins: targeting FATP2 as a gatekeeper involved in the transport of exogenous fatty acids. Medchemcomm. 2016;7:612–22.
Perez VM, Gabell J, Behrens M, Wase N, DiRusso CC, Black PN. Deletion of fatty acid transport protein 2 (FATP2) in the mouse liver changes the metabolic landscape by increasing the expression of PPARalpha-regulated genes. J Biol Chem. 2020;295:5737–50.
Chen Y, Yan Q, Lv M, Song K, Dai Y, Huang Y, et al. Involvement of FATP2-mediated tubular lipid metabolic reprogramming in renal fibrogenesis. Cell Death Dis 2020;11:994.
Wan Z, Fu S, Wang Z, Xu Y, Zhou Y, Lin X, et al. FABP4-mediated lipid droplet formation in Streptococcus uberis-infected macrophages supports host defence. Vet Res. 2022;53:90.
Baines RJ, Chana RS, Hall M, Febbraio M, Kennedy D, Brunskill NJ. CD36 mediates proximal tubular binding and uptake of albumin and is upregulated in proteinuric nephropathies. Am J Physiol Ren Physiol. 2012;303:F1006–14.
Li Y, Yang P, Zhao L, Chen Y, Zhang X, Zeng S, et al. CD36 plays a negative role in the regulation of lipophagy in hepatocytes through an AMPK-dependent pathway. J Lipid Res. 2019;60:844–55.
Lu XY, Shi XJ, Hu A, Wang JQ, Ding Y, Jiang W, et al. Feeding induces cholesterol biosynthesis via the mTORC1-USP20-HMGCR axis. Nature. 2020;588:479–84.
Istvan ES, Palnitkar M, Buchanan SK, Deisenhofer J. Crystal structure of the catalytic portion of human HMG-CoA reductase: insights into regulation of activity and catalysis. EMBO J. 2000;19:819–30.
Carling D, Clarke PR, Zammit VA, Hardie DG. Purification and characterization of the AMP-activated protein kinase. Copurification of acetyl-CoA carboxylase kinase and 3-hydroxy-3-methylglutaryl-CoA reductase kinase activities. Eur J Biochem. 1989;186:129–36.
Soto-Acosta R, Bautista-Carbajal P, Cervantes-Salazar M, Angel-Ambrocio AH, Del Angel RM. DENV up-regulates the HMG-CoA reductase activity through the impairment of AMPK phosphorylation: a potential antiviral target. PLoS Pathog. 2017;13:e1006257.
Baldelli S, Aquilano K, Ciriolo MR. Punctum on two different transcription factors regulated by PGC-1alpha: nuclear factor erythroid-derived 2-like 2 and nuclear respiratory factor 2. Biochim Biophys Acta. 2013;1830:4137–46.
Aquilano K, Baldelli S, Pagliei B, Cannata SM, Rotilio G, Ciriolo MR. p53 orchestrates the PGC-1alpha-mediated antioxidant response upon mild redox and metabolic imbalance. Antioxid Redox Signal. 2013;18:386–99.
Merry TL, Ristow M. Nuclear factor erythroid-derived 2-like 2 (NFE2L2, Nrf2) mediates exercise-induced mitochondrial biogenesis and the anti-oxidant response in mice. J Physiol. 2016;594:5195–207.
Hozhabri Y, Sadeghi A, Nazari-Robati M, Bahri F, Salimi F, Abolhassani M, et al. Effects of trehalose on NFE2L2, catalase, and superoxide dismutase in the kidney of aged rats. Mol Biol Res Commun. 2022;11:29–36.
Vergeade A, Bertram CC, Bikineyeva AT, Zackert WE, Zinkel SS, May JM, et al. Cardiolipin fatty acid remodeling regulates mitochondrial function by modifying the electron entry point in the respiratory chain. Mitochondrion. 2016;28:88–95.
Vernier M, Giguere V. Aging, senescence and mitochondria: the PGC-1/ERR axis. J Mol Endocrinol. 2021;66:R1–R14.
Yu BH, Liu Y, Deng P, Szymanski J, Li J, Luo X, et al. PGC-1α controls skeletal stem cell fate and bone-fat balance in osteoporosis and skeletal aging by inducing TAZ. Cell Stem Cell. 2018;23:193–209.e5.
Tsai YT, Li Y, Ryu J, Su PY, Cheng CH, Wu WH, et al. Impaired cholesterol efflux in retinal pigment epithelium of individuals with juvenile macular degeneration. Am J Hum Genet. 2021;108:903–18.
Acknowledgements
This research was supported by the National Eye Institute (NEI, R01EY028917), the Prevention of Blindness Society of Metropolitan Washington (POB), and NCI-P30 CA051008, the GUMC institutional support for shared resources.
Author information
Authors and Affiliations
Contributions
SZ designed and performed experiments, analyzed data, and drafted the manuscript, KT performed experiments, analyzed data, and drafted the manuscript, JH performed experiments and edited the manuscript, JG performed experiments and analyzed data, SO performed experiments, JS performed experiments, NG designed the study, performed experiments and wrote the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethics approval
Our studies did not include human participants or patient data. The animal studies were approved by the Georgetown University Institutional Animal Care and Use Committee (GUIACUC Protocol 2016-1146).
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Edited by Michelangelo Campanella
Supplementary information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Zhou, S., Taskintuna, K., Hum, J. et al. PGC-1α repression dysregulates lipid metabolism and induces lipid droplet accumulation in the retinal pigment epithelium. Cell Death Dis 15, 385 (2024). https://doi.org/10.1038/s41419-024-06762-y
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41419-024-06762-y